Novo Nordisk’s Oral Diabetes Drug Reduces Heart-Related Risks by 14% in Study

On Monday, Novo Nordisk (NYSE: NVO) said an oral version of its drug semaglutide, helped significantly reduce the risk of cardiovascular events in patients in a late-stage study.

The drug, Rybelsus, helped reduce the risk of these events, including cardiovascular death, non-fatal heart attack, and stroke, by 14% compared to placebo, meeting the main goal of the trial.

The study tested the drug as an adjunct to standard of care in 9,650 patients with type 2 diabetes and established cardiovascular disease and/or chronic kidney disease, the company said.

Novo Nordisk (NYSE: NVO) expects to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the year.

The drugmaker said detailed results from the study will be presented at a scientific conference next year.

(Source: ReutersReuters)

Novo Nordisk NYSE: NVO

Edward Cooke

Edward Cooke is a financial analyst, freelance writer, and editor. He has six years of experience in financial journalism. He has an in-depth understanding of equities markets, tracking major indices and providing real-time analysis on stock price movements, corporate earnings, and market sentiment.

See Full Bio